Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Recruiting

Phase 2

ALN-ANG3 & EvinacumabStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07271186

Conditions

Diabetic Kidney Disease (DKD)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

ALN-ANG3

Evinacumab

ALN-ANG3 placebo

Evinacumab placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-13. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-02-04.